Berberine Inhibits Proliferation and Down-Regulates Epidermal Growth Factor Receptor through Activation of Cbl in Colon Tumor Cells

Wang, Lihong; Cao, Hailong; Lu, Ning; Liu, Liping; Wang, Bangmao; Hu, Tianhui; Israel, Dawn A.; Peek Jr, Richard M.; Polk, D. Brent; Yan, Fang
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Berberine, an isoquinoline alkaloid, is an active component of Ranunculaceae and Papaveraceae plant families. Berberine has been found to suppress growth of several tumor cell lines in vitro through the cell-type-dependent mechanism. Expression and activation of epidermal growth factor receptor (EGFR) is increased in colonic precancerous lesions and tumours, thus EGFR is considered a tumour promoter. The aim of this study was to investigate the effects and mechanisms of berberine on regulation of EGFR activity and proliferation in colonic tumor cell lines and in vivo. We reported that berberine significantly inhibited basal level and EGF-stimulated EGFR activation and proliferation in the immorto Min mouse colonic epithelial (IMCE) cells carrying the APCmin mutation and human colonic carcinoma cell line, HT-29 cells. Berberine acted to inhibit proliferation through inducing G1/S and G2/M cell cycle arrest, which correlated with regulation of the checkpoint protein expression. In this study, we also showed that berberine stimulated ubiquitin ligase Cbl activation and Cbl's interaction with EGFR, and EGFR ubiquitinylation and down-regulation in these two cell lines in the presence or absence of EGF treatment. Knock-down Cbl expression blocked the effects of berberine on down-regulation of EGFR and inhibition of proliferation. Furthermore, berberine suppressed tumor growth in the HT-29 cell xenograft model. Cell proliferation and EGFR expression level was decreased by berberine treatment in this xenograft model and in colon epithelial cells of APCmin/+ mice. Taken together, these data indicate that berberine enhances Cbl activity, resulting in down-regulation of EGFR expression and inhibition of proliferation in colon tumor cells.


Related Articles

  • Single Domain Antibodies: A New Concept for Epidermal Growth Factor Receptor and EGFRvIII Targeting. Omidfar, Kobra; Shirvani, Zaynab // DNA & Cell Biology;Jun2012, Vol. 31 Issue 6, p1015 

    Epidermal growth factor receptor (EGFR) is one of the major molecular targets for cancer diagnosis and therapy. EGFR and EGFRvIII, mutated form of EGFR, have been identified as participating in pathogenesis of some forms of human cancers. Monoclonal antibodies (mAbs) targeting EGFR/EGFRvIII have...

  • Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Montagut, Clara; Dalmases, Alba; Bellosillo, Beatriz; Crespo, Marta; Pairet, Silvia; Iglesias, Mar; Salido, Marta; Gallen, Manuel; Marsters, Scot; Tsai, Siao Ping; Minoche, André; Somasekar, Seshagiri; Serrano, Sergi; Himmelbauer, Heinz; Bellmunt, Joaquim; Rovira, Ana; Settleman, Jeff; Bosch, Francesc; Albanell, Joan // Nature Medicine;Feb2012, Vol. 18 Issue 2, p221 

    Antibodies against epidermal growth factor receptor (EGFR)-cetuximab and panitumumab-are widely used to treat colorectal cancer. Unfortunately, patients eventually develop resistance to these agents. We describe an acquired EGFR ectodomain mutation (S492R) that prevents cetuximab binding and...

  • Combinational treatment with microRNA-133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR. JIANYU ZHOU; LV LV; CHANGWEI LIN; GUI HU; YIHANG GUO; MEIRONG WU; BUNING TIAN; XIAORONG LI // Molecular Medicine Reports;2015, Vol. 12 Issue 4, p5407 

    Colorectal cancer (CRC) is the third most common cancer with a very poor prognosis predominantly due to its high rate of tumor invasion and migration, and its resistance to anti-epidermal growth factor receptor (EGFR) therapy. Although CRC has been widely studied, the underlying molecular...

  • Comparison of K-ras mutations in lung, colorectal and gastric cancer. NANQIU PENG; XINTAI ZHAO // Oncology Letters;2014, Vol. 8 Issue 2, p561 

    K-ras is involved in the EGFR pathway that regulates cell survival, motility and proliferation, as well as angiogenesis and metastasis. It is also essential for carcinogenesis. The K-ras mutation status can be used to predict the therapeutic efficacy of targeted drugs such as cetuximab. The aim...

  • Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome. Ming-Yii Huang; Jaw-Yuan Wang; Meng-Lin Huang; Hui-Jen Chang; Shiu-Ru Lin // International Journal of Molecular Sciences;Feb2013, Vol. 14 Issue 2, p4121 

    Using the comprehensive approach to selecting polymorphisms to date, we sought to examine whether recurrence in colorectal cancer was associated with inherited variation in three genes involved in DNA repair and cell proliferation. Three polymorphisms, which are excision repair...

  • MicroRNA-153 Inhibits Osteosarcoma Cells Proliferation and Invasion by Targeting TGF-β2. Niu, Guangfeng; Li, Bin; Sun, Li; An, Chenggong // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Increasing evidence indicates that microRNAs (miRNAs), a class of small noncoding RNAs, participate in almost every step of cellular processes. MiRNAs are aberrantly expressed in human cancers and contribute to cancer development and progression. Study of miRNAs may provide a new clue for...

  • KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. Messner, Isabelle; Cadeddu, Giuseppe; Huckenbeck, Wolfgang; Knowles, Helen; Gabbert, Helmut; Baldus, Stephan; Schaefer, Karl-Ludwig // Journal of Cancer Research & Clinical Oncology;Feb2013, Vol. 139 Issue 2, p201 

    Purpose: Targeted therapies using the anti-EGFR antibodies panitumumab (Pmab) or cetuximab (Cmab) are currently restricted to patients with metastatic colorectal adenocarcinoma whose tumours do not show a mutation in KRAS. However, recent retrospective studies indicated that patients with...

  • EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma. Yi Huang; Tao Yu; Xiaoyue Fu; Jiao Chen; Chunjie Li; Yichao Xia; Zhuoyuan Zhang; Longjiang Li // BMC Cell Biology;2013, Vol. 14 Issue 1, p1 

    Background: Epidermal growth factor receptor (EGFR) is involved in the development of many human malignant tumors and plays an important role in tumor growth and metastasis. Antagonists of EGFR can suppress the growth of several malignancies; however, their therapeutic effect in adenoid cystic...

  • Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Hattar, Katja; Savai, Rajkumar; Subtil, Florentine; Wilhelm, Jochen; Schmall, Anja; Lang, Dagmar; Goldmann, Torsten; Eul, Bastian; Dahlem, Gabriele; Fink, Ludger; Schermuly, Ralph-Theo; Banat, Gamal-Andre; Sibelius, Ulf; Grimminger, Friedrich; Vollmer, Ekkehard; Seeger, Werner; Grandel, Ulrich // Cancer Immunology, Immunotherapy;Feb2013, Vol. 62 Issue 2, p309 

    Lung cancer is frequently complicated by pulmonary infections which may impair prognosis of this disease. Therefore, we investigated the effect of bacterial lipopolysaccharides (LPS) on tumor proliferation in vitro in the non-small cell lung cancer (NSCLC) cell line A549, ex vivo in a tissue...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics